Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Shelley Herbrich"'
Autor:
Natalia Baran, Alessia Lodi, Yogesh Dhungana, Shelley Herbrich, Meghan Collins, Shannon Sweeney, Renu Pandey, Anna Skwarska, Shraddha Patel, Mathieu Tremblay, Vinitha Mary Kuruvilla, Antonio Cavazos, Mecit Kaplan, Marc O. Warmoes, Diogo Troggian Veiga, Ken Furudate, Shanti Rojas-Sutterin, Andre Haman, Yves Gareau, Anne Marinier, Helen Ma, Karine Harutyunyan, May Daher, Luciana Melo Garcia, Gheath Al-Atrash, Sujan Piya, Vivian Ruvolo, Wentao Yang, Sriram Saravanan Shanmugavelandy, Ningping Feng, Jason Gay, Di Du, Jun J. Yang, Fieke W. Hoff, Marcin Kaminski, Katarzyna Tomczak, R. Eric Davis, Daniel Herranz, Adolfo Ferrando, Elias J. Jabbour, M. Emilia Di Francesco, David T. Teachey, Terzah M. Horton, Steven Kornblau, Katayoun Rezvani, Guy Sauvageau, Mihai Gagea, Michael Andreeff, Koichi Takahashi, Joseph R. Marszalek, Philip L. Lorenzi, Jiyang Yu, Stefano Tiziani, Trang Hoang, Marina Konopleva
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-20 (2022)
Notch1 is frequently activated promoting T-cell acute lymphoblastic leukaemia (T-ALL). Here, the authors show that Notch1 induces oxidative phosphorylation dependency in T-ALL and synergism when inhibiting both mitochondrial complex I and glutaminoly
Externí odkaz:
https://doaj.org/article/3982d909df0b4071b01a6f0797433bde
Autor:
R Eric Davis, Marina Konopleva, Natalia Baran, Gheath Al-Atrash, Naval Daver, Shelley Herbrich, Tianyu Cai, Connie Weng, Marisa J L Aitken, Sean M Post, Jared Henderson, Chunhua Shi, Guillame Richard-Carpentier, Guy Sauvageau, Keith Baggerly, Dongxing Zha, Ondrej Havranek
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Background Acute myeloid leukemia (AML) stem cells (LSCs) are capable of surviving current standard chemotherapy and are the likely source of deadly, relapsed disease. While stem cell transplant serves as proof-of-principle that AML LSCs can be elimi
Externí odkaz:
https://doaj.org/article/ec9bd9e5fbea4ec3b2a31d083604c1bd
Autor:
Zhihong Zeng, Abhishek Maiti, Shelley Herbrich, Tianyu Cai, Antonio Cavazos, Taylor Manzella, Helen Ma, Kala Hayes, Jairo Matthews, Courtney D. DiNardo, Naval G. Daver, Marina Y. Konopleva
Publikováno v:
Cancer. 129:531-540
A recent breakthrough therapy combining the BCL-2 inhibitor venetoclax with hypomethylating agents (HMAs) targeting DNA methyltransferase has improved outcomes for patients with acute myeloid leukemia (AML), but the responses and long-term survival i
Publikováno v:
Regular and Young Investigator Award Abstracts.
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Jielin Liu, Swetha Anandhan, Sreyashi Basu, Yulong Chen, Sangeeta Goswami, Ashwat Nagarajan, Shelley Herbrich, Liangwen Xiong, Baoxiang Guan, Padmanee Sharma
Publikováno v:
Cancer Research. 83:3277-3277
Immune checkpoint therapy (ICT) has recently revolutionized the treatment paradigm for various types of cancer. However, despite the unprecedented safety and efficacy profile compared to traditional treatment options, many patients do not respond to
Autor:
Shelley Herbrich, Natalia Baran, Tianyu Cai, Connie Weng, Marisa J L Aitken, Sean M Post, Jared Henderson, Chunhua Shi, Ondrej Havranek, Guillame Richard-Carpentier, Guy Sauvageau, Keith Baggerly, Gheath Al-Atrash, R Eric Davis, Naval Daver, Dongxing Zha, Marina Konopleva
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
BackgroundAcute myeloid leukemia (AML) stem cells (LSCs) are capable of surviving current standard chemotherapy and are the likely source of deadly, relapsed disease. While stem cell transplant serves as proof-of-principle that AML LSCs can be elimin
Autor:
Alix Derreal, Peter P. Ruvolo, Vinitha M. Kurvilla, Anna Skwarska, Qi Zhang, Michael Andreeff, Sébastien Banquet, Andrew H. Wei, Vivian Ruvolo, Natalia Baran, Paul Panis, Marina Konopleva, Shelley Herbrich, Ensar Halilovic, Donia M Moujalled, Erick Morris
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:S220-S221
Autor:
Shelley Herbrich, Marina Konopleva, Antonio Cavazos, Naval Daver, Zhihong Zeng, Taylor Manzella, Tianyu Cai, Jairo Matthews, Courtney Dinardo
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S203
Background Acute myeloid leukemia (AML) is a hematopoietic malignancy with an increased incidence among older patients. The long-term survival of older AML patients treated with established therapies remains poor. The BCL-2 inhibitor venetoclax with
Autor:
Marina Konopleva, Anna Skwarska, Shelley Herbrich, Vivian Ruvolo, Erick Morris, Peter P. Ruvolo, Donia M Moujalled, Qi Zhang, Michael Andreff, Ensar Halilovic, Natalia Baran, Andrew H. Wei
Publikováno v:
Cancer Research. 79:342-342
Myeloid cell leukemia 1 (Mcl-1) is one of the key anti-apoptotic Bcl-2 family proteins that binds and neutralizes pro-apoptotic BIM, BAX and BAK at the mitochondrial outer membrane, preventing cytochrome c release and caspase activation. Selective up